Development of a prognostic model related to homologous recombination deficiency in glioma based on multiple machine learning
The prognostic model based on the HRD score threshold and associated genes in glioma offers new insights into the genomic and immunological landscapes, potentially guiding therapeutic strategies. The differential immune profiles associated with HRD-risk groups could inform immunotherapeutic interventions, with our findings paving the way for personalized medicine in glioma treatment.
Authors
- Tao Xu (ORCID: https://orcid.org/0000-0002-8635-2263)
- Haotian Shen (ORCID: https://orcid.org/0000-0002-5230-305X)
- Hongxiang Wang (ORCID: https://orcid.org/0000-0003-4839-3985)
- Chao Ma (ORCID: https://orcid.org/0000-0003-1444-4668)
- Li-Jun Hou (ORCID: https://orcid.org/0000-0002-1803-3201)
- Zhenyu Gong (ORCID: https://orcid.org/0000-0002-7376-4816)
- Dejun Wu (ORCID: https://orcid.org/0000-0003-1693-1750)
- Dairan Zhou
Institutions
- Second Military Medical University (CN)
- Anhui Medical University (CN)
- TUM Klinikum (DE)
- Shanghai Changzheng Hospital (CN)
- Changhai Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Technical University of Munich (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.3389/fimmu.2024.1452097
- Citations
- 4
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.75